[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.226.244.70. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
March 1993

Pharmacologic and Surgical Enhancement of Composite Graft Survival

Author Affiliations

From the Division of Otolaryngology—Head and Neck Surgery, Stanford (Calif) University (Drs Fann and Goode) and the University of California San Francisco (Dr Hartman). Dr Fann is now doing a fellowship with Walter E. Berman, MD, in private practice in Beverly Hills, Calif.

Arch Otolaryngol Head Neck Surg. 1993;119(3):313-319. doi:10.1001/archotol.1993.01880150069010
Abstract

• A previously described rabbit ear model was used to address the following issues: (1) the role of surgical delay in composite tissue transfer, (2) optimal enhancement of graft survival using the corticosteroid methylprednisolone, (3) pharmacologic salvage of the failing composite graft, and (4) efficacy of a nonsteroidal dual cyclooxygenase/lipooxygenase inhibitor (SK&F 86002) in enhancing graft survival. Preoperative and immediate postoperative steroid treatment groups exhibited a significant improvement in graft survival area compared with the untreated control group. Preoperative initiation of steroid therapy was more effective than a strictly postoperative regimen. SK&F 86002, advance preparation of the recipient bed, and delayed steroid administration did not improve graft survival compared with the untreated control group. The most promising treatment, preoperative initiation of steroid therapy, was further evaluated in a double-blinded placebo-controlled study. The steroid group demonstrated a significantly improved mean survival area, as well as mean graft weight, compared with the placebo control group.

(Arch Otolaryngol Head Neck Surg. 1993;119:313-319)

×